Vimpat Articles
UCB heading for growth phase as new products drive 2012 sales
28 February 2013
UCB's Vimpat effective in achieving seizure control in patients with refractory epilepsy
8 July 2012
More news from EMA/CHMP September meeting
26 September 2011
UCB presents new data on Vimpat and health care costs associated with epilepsy at IEC meeting
1 September 2011
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
Belgium’s UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
1 February 2010
UCB's Vimpat goes on sale in USA
28 May 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
Vimpat approved in Scotland to treat epilepsy
16 February 2009
UCB launches Vimpat in UK
20 October 2008
UCB withdraws Vimpat application to EMEA
6 October 2008
UCB to cut 17% of staff in major restructuring
8 September 2008
UCB shares fall 8.3% as FDA rejects Vimpat for DNP
4 August 2008
Vimpat gets nod for epilepsy from CHMP
7 July 2008
Showing 1-15 of 15 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
